HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT INDUCED BY RECOMBINANT HUMAN INTERFERON-ALPHA-A IN CHRONIC MYELOGENOUS LEUKEMIA
HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT INDUCED BY RECOMBINANT HUMAN INTERFERON-ALPHA-A IN CHRONIC MYELOGENOUS LEUKEMIA
复制标题
DOI：
10.1056/nejm198604243141701
复制
发表时间：
1986-04-24
影响因子：
158.5
通讯作者：
GUTTERMAN, JU
中科院分区：
文献类型：
--
作者：
TALPAZ, M;KANTARJIAN, HM;GUTTERMAN, JU
我们用重组人干扰素αA(Roferon-A)治疗了17例费城染色体阳性的慢性粒细胞白血病患者(其中4例未接受治疗，13例接受羟基脲或丁硫丹治疗不足6个月)。干扰素用量为5次。在诱导治疗期间，每天肌肉注射每平方米身体表面积106个单位。14例患者对治疗有反应，其中13例血液学缓解，1例血液学部分缓解。这些患者中白细胞的中位数从60.9倍下降。103到3.4倍。每微升103个，血小板数量的中位数从476倍下降。103到231次。每微升103。在治疗前有脾肿大的5名有反应的患者中，有4名患者的脾大小恢复正常，1名患者的脾大小减少了75%，尽管它仍然很大。骨髓细胞密度从中位数92.5%下降到57.5%。在6名血液学缓解的患者中，至少一次检查观察到费城细胞完全抑制。在14名有反应的患者中，11人接受了9至15个月的干扰素治疗。一名患者在治疗过程中复发，两名患者因毒性而暂时中断治疗。这些数据是初步的，还需要进一步的证实，但它们表明，重组人干扰素αA在诱导大多数良性期慢性髓细胞白血病患者的血液学缓解以及抑制其中一些患者的费城染色体方面是有效的。
We treated 17 patients who had Philadelphia-chromosome-positive chronic myelogenous leukemia (4 of whom had not received therapy and 13 of whom had been treated with hydroxyurea or busulfan for less than six months) with recombinant human interferon alphaA (Roferon-A). The interferon was given as 5 .times. 106 units per square meter of body-surface area per day intramuscularly during induction therapy. Fourteen patients responded to the treatment, of whom 13 had a hematologic remission and 1 had a partial hematologic remission. The median number of white cells in those patients declined from 60.9 .times. 103 to 3.4 .times. 103 per microliter, and the median number of platelets decreased from 476 .times. 103 to 231 .times. 103 per microliter. Among the five responding patients who had splenomegaly before treatment, the spleen size returned to normal in four and decreased by 75 percent in one, although it remained enlarged. Bone marrow cellularity declined from a median of 92.5 percent to a median of 57.5 percent. In six of the patients with hematologic remission, complete suppression of Philadelphia cells was observed on at least one examination. Of the 14 patients who responded, 11 have received the interferon therapy for 9 to 15 months. One patient relapsed during the treatment, and the treatment has been temporarily interrupted in two patients because of toxicity. These data are preliminary and will need further confirmation, but they suggest that recombinant human interfereon alphaA is effective in inducing hematologic remission in most patients with benign-phase chronic myelogenous leukemia and in suppressing the Philadelphia chromosome in some of these patients.